Profound Medical is a public medical device company based in Toronto, Canada. The company was commerializing an incision-free therapies for the ablation of diseased tissue. Their flagship product, TULSA-PRO®, integrates real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control to provide precise, radiation-free ablation of prostate tissue. Profound is listed on the NASDAQ,
Prostate cancer
CTI LSF II
Lead
n/a
November 10, 2016
IPO on the NASDAQ
PIPE
Profound’s MRI guided ablation not only improves survival outcome but is also significantly less invasive compared to traditional approach
